Curated News
By: NewsRamp Editorial Staff
June 11, 2026
VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq
TLDR
- VERAXA Biotech (NASDAQ: VRXA) now trades on Nasdaq after closing its business combination, offering exposure to innovative cancer therapies.
- VERAXA's BiTAC platform uses bispecific T-cell engagers and antibody-drug conjugates to selectively target cancer cells while sparing healthy tissue.
- VERAXA's targeted cancer therapies aim to improve patient outcomes by reducing harm to healthy cells, advancing tomorrow's cancer treatment.
- VERAXA's BiTAC platform was born from breakthroughs at the European Molecular Biology Laboratory, a top life science research institute.
Impact - Why it Matters
This news matters because VERAXA Biotech's novel BiTAC platform has the potential to revolutionize cancer treatment by offering more targeted therapies with fewer side effects. The successful business combination and Nasdaq listing provide the company with the capital and visibility needed to advance its pipeline toward clinical trials, bringing hope to patients with difficult-to-treat cancers. Investors and the biotech community should watch for upcoming clinical data that could validate this innovative approach.
Summary
VERAXA Biotech (NASDAQ: VRXA) has announced the successful closing of its business combination with Voyager Acquisition Corp., marking a significant milestone for the clinical-stage biotechnology company. The newly formed entity, VERAXA Biotech AG, will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. VERAXA is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue. The company's lead BiTAC-TCE candidate recently demonstrated favorable efficacy and safety characteristics in preclinical data presented at the AACR Annual Meeting 2026.
To support its clinical development programs, VERAXA has secured significant financing, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million. These proceeds are expected to advance the BiTAC-TCE and BiTAC-ADC programs toward clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company's proprietary BiTAC platform represents a novel approach to cancer therapy, leveraging bispecific antibodies to engage T cells and deliver cytotoxic payloads directly to tumor cells, potentially reducing off-target effects.
Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, brings a team of experienced executives with expertise in investing, operations, and medical innovation. The combination is expected to accelerate VERAXA's mission to become a premier engine for the discovery and development of next-generation antibody-based therapeutics. For more information, visit the original release on NEWMEDIAWIRE and the full press release at https://ibn.fm/ka00j. Regular updates about VERAXA Biotech can be found at www.veraxa.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq
